MX2009009226A - Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial. - Google Patents

Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.

Info

Publication number
MX2009009226A
MX2009009226A MX2009009226A MX2009009226A MX2009009226A MX 2009009226 A MX2009009226 A MX 2009009226A MX 2009009226 A MX2009009226 A MX 2009009226A MX 2009009226 A MX2009009226 A MX 2009009226A MX 2009009226 A MX2009009226 A MX 2009009226A
Authority
MX
Mexico
Prior art keywords
rsv
treatment
respiratory syncytial
syncytial virus
recombinant antibodies
Prior art date
Application number
MX2009009226A
Other languages
English (en)
Inventor
Johan Lantto
Henriette Schjoenning Nielsen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/000113 external-priority patent/WO2007101441A1/en
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX2009009226A publication Critical patent/MX2009009226A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se dan a conocer anticuerpos policlonales novedosos, los cuales fijan como objetivo el virus respiratorio sincitial (RSV), así como también moléculas de anticuerpos de alta afinidad novedosas que son reactivas con el RSV. Los anticuerpos policlonales pueden comprender moléculas de anticuerpos las cuales son reactivas con tanto la proteína F del RSV como la proteína G del RSV y preferiblemente los anticuerpos policlonales fijan como objetivo una variedad de epítopos en esas proteínas. Las moléculas de anticuerpos de la invención han mostrado una eficacia superior in vitro y/o in vivo. También se dan a conocer métodos para producir los anticuerpos de la invención así como también métodos para su uso en el tratamiento o prevención de la infección con el RSV.
MX2009009226A 2007-03-06 2008-03-05 Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial. MX2009009226A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/DK2007/000113 WO2007101441A1 (en) 2006-03-06 2007-03-06 Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
DKPA200701291 2007-09-07
US97138707P 2007-09-11 2007-09-11
PCT/DK2008/050053 WO2008106980A2 (en) 2007-03-06 2008-03-05 Recombinant antibodies for treatment of respiratory syncytial virus infections

Publications (1)

Publication Number Publication Date
MX2009009226A true MX2009009226A (es) 2009-10-28

Family

ID=39687110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009226A MX2009009226A (es) 2007-03-06 2008-03-05 Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.

Country Status (13)

Country Link
US (2) US7879329B2 (es)
EP (1) EP2134747A2 (es)
JP (1) JP2010534057A (es)
KR (1) KR20090127341A (es)
CN (1) CN101679513A (es)
AU (1) AU2008224259A1 (es)
BR (1) BRPI0808673A2 (es)
CA (1) CA2678628A1 (es)
IL (1) IL200330A0 (es)
MX (1) MX2009009226A (es)
RU (1) RU2009136677A (es)
WO (1) WO2008106980A2 (es)
ZA (1) ZA200905990B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
PT2121920E (pt) * 2007-03-01 2011-10-03 Symphogen As Método de clonagem de anticorpos cognatos
KR20090127341A (ko) * 2007-03-06 2009-12-10 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 항체
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
WO2009030237A2 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
MX2011001930A (es) * 2008-08-29 2011-04-21 Symphogen As Metodo para clonar anticuerpos derivados de aves.
WO2010129609A2 (en) * 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
IN2012DN01328A (es) * 2009-08-13 2015-06-05 Crucell Holland Bv
EP2486411A2 (en) 2009-10-09 2012-08-15 Symphogen A/S Multiplex quantitation of individual recombinant proteins in a mixture by signature peptides and mass spectrometry
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
EP2625295B1 (en) * 2010-10-08 2019-03-13 President and Fellows of Harvard College High-throughput immune sequencing
GB201019240D0 (en) 2010-11-15 2010-12-29 Vib Vzw Respiratory syncytical virus vaccine
EP3345922A1 (en) 2011-03-09 2018-07-11 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
EP2780366A2 (en) 2011-11-17 2014-09-24 AIMM Therapeutics B.V. Rsv g protein specific antibodies
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
US9546219B2 (en) * 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
EA035846B1 (ru) * 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
HUE048855T2 (hu) 2014-01-15 2020-08-28 Medimmune Llc RSV-re specifikus ellenanyagok és azok funkcionális részei
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
AU2017345786B2 (en) 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
BR112019008063A2 (pt) 2016-10-21 2019-07-02 Adimab Llc anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
WO2018140242A1 (en) * 2017-01-27 2018-08-02 Vanderbilt University Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
AU2021227687B2 (en) 2020-02-26 2023-02-23 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
CN112225803B (zh) * 2020-10-20 2022-08-05 长春百克生物科技股份公司 纳米抗体及其应用
CN112442120A (zh) * 2020-11-25 2021-03-05 苏州大学 抗严重急性呼吸系统综合征ii型冠状病毒sars-cov-2的中和抗体
CN113249333B (zh) * 2021-03-16 2023-06-02 贵州省人民医院 一种分泌抗呼吸道合胞病毒单克隆抗体的杂交瘤细胞株rsvn4c3
CN114134118B (zh) * 2021-11-22 2023-05-09 南方医科大学南方医院 一种永生化人喉环后区细胞及其构建方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US607751A (en) * 1898-07-19 Wire-stretcher
US5639853A (en) * 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
EP0539522B1 (en) 1990-07-19 1998-12-30 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Improved immunotherapeutic method of preventing or treating viral respiratory tract disease
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
DK0671927T3 (da) * 1992-09-16 2003-04-22 Us Gov Health & Human Serv Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU710713B2 (en) 1994-08-25 1999-09-30 Stichting Instituut Voor Dierhouderij En Diergezondheid Antigenic peptides derived from the G protein of RSV for type- and subtype-specific diagnosis of respiratory syncytial virus (RSV) infection
US5922344A (en) * 1995-02-10 1999-07-13 Abbott Laboratories Product for prevention of respiratory virus infection and method of use
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
WO1997010846A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
DK1265928T3 (da) * 2000-01-27 2010-11-15 Medimmune Llc RSV-neutraliserende antistoffer med ultra høj affinitet
US20050175986A1 (en) * 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
ES2316487T5 (es) * 2000-10-18 2019-05-13 The Government Of The Us Secretary Department Of Health And Human Services Composiciones y métodos para modular la inmunidad e infección de RSV
US20040161846A1 (en) 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
JP2005533861A (ja) * 2002-07-25 2005-11-10 メデュームン，インコーポレーテッド 抗ＲＳＶ、抗ｈＭＰＶ、および抗ＰＩＶ抗体を使用するＲＳＶ、ｈＭＰＶ、およびＰＩＶの治療法と予防法
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
MXPA05006724A (es) * 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
US6821450B2 (en) * 2003-01-21 2004-11-23 Hewlett-Packard Development Company, L.P. Substrate and method of forming substrate for fluid ejection device
GB0306618D0 (en) 2003-03-22 2003-04-30 Univ Newcastle Antibody
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2004092207A2 (en) 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2006023029A2 (en) 2004-06-16 2006-03-02 The Johns Hopkins University The cysteine-rich region of respiratory syncytial virus and methods of use therefor
RU2426795C2 (ru) * 2004-07-20 2011-08-20 Симфоген А/С Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии
CA2574062A1 (en) 2004-07-20 2006-01-26 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
WO2006034292A2 (en) * 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2007065433A2 (en) 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
TW200846362A (en) 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
KR20090127341A (ko) * 2007-03-06 2009-12-10 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 항체

Also Published As

Publication number Publication date
WO2008106980A3 (en) 2008-10-30
CN101679513A (zh) 2010-03-24
BRPI0808673A2 (pt) 2014-08-12
US7879329B2 (en) 2011-02-01
US20110189171A1 (en) 2011-08-04
AU2008224259A1 (en) 2008-09-12
KR20090127341A (ko) 2009-12-10
JP2010534057A (ja) 2010-11-04
RU2009136677A (ru) 2011-04-20
WO2008106980A2 (en) 2008-09-12
IL200330A0 (en) 2010-04-29
EP2134747A2 (en) 2009-12-23
US20080226630A1 (en) 2008-09-18
CA2678628A1 (en) 2008-09-12
ZA200905990B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
MX2009009226A (es) Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2009040134A8 (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
EA201200277A1 (ru) Антитела против респираторного синцитиального вируса (pcb) и способы их применения
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
WO2006034292A3 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2007058823A3 (en) Anti-egfr antibodies
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus
WO2009055711A3 (en) Anti-rsv g protein antibodies
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
EA200700136A1 (ru) Анти-cd154-антитела
WO2007068750A3 (en) Immunoglobulins directed against nogo
CY1113630T1 (el) Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
WO2006020773A3 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
WO2007047112A3 (en) Anti-myostatin antibodies
WO2008098917A3 (en) Novel antibodies against igf-ir
TW200510459A (en) RG1 antibodies and uses thereof
WO2010002478A3 (en) Glycopeptide and uses thereof
MY148451A (en) Antibodies against il-25
WO2007109370A3 (en) Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
MX2010001237A (es) Nuevos anticuerpos.
WO2008085987A3 (en) Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
WO2017021815A3 (en) Monoclonal antibodies specifically for phosphoprotein of the human respiratory syncytial virus and the methods of use
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration